Clinical trial · Interventional
Artificial Intelligence Supporting CAncer Patients Across Europe - the ASCAPE Project
NCT04879563CI-TRIAL-00082728ASCAPEactive not recruitingPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
ASCAPE (Artificial intelligence Supporting CAncer Patients across Europe) is a collaborative research project involving 15 partners from 7 countries, including academic medical centers, SMEs (small and medium-sized enterprises), research centers and universities, aiming to leverage the recent advances in Big Data and AI (Artificial Intelligence) to support cancer patients' Quality of Life (QoL) and health status. Specifically, ASCAPE aims to provide personalized- and AI-based predictions for QoL issues in breast- and prostate cancer patients as well as suggest potential interventions to their physicians. This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 875351.
Conditions
Conditions (5)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
| Quality of Life | — | UNRESOLVED | — |
| Survivorship | — | UNRESOLVED | — |
| Toxicity | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| ASCAPE-based follow-up strategy | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- ASCAPE-based follow-up strategy
- description
- Follow-up through ASCAPE platform including AI-based predictions for health-related QoL issues and suggestions for personalized interventions.
- interventionNames
- Other: ASCAPE-based follow-up strategy
Primary outcomes (1)
- measure
- Patients' experience using ASCAPE-based follow-up
- timeFrame
- At the end of intervention (month 12)
- description
- Patients' experience to be followed with the help of an AI-based system per se, patients' satisfaction with this type of follow-up, potential barriers and facilitators of using wearables during follow-up, and motivation for following interventions based on AI-based follow-up
Secondary outcomes (6)
- measure
- Patients' engagement to ASCAPE-based follow-up
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
The patient selection process varies among the different study sites. Three Hospitals (Sismanogleio General Hospital Athens (SGHA), Örebro University Hospital (ÖUH), Uppsala University Hospital (UUH)) will include patients with newly diagnosed breast- (ÖUH, UUH) or prostate cancer (SGHA, ÖUH) who are eligible for curative treatment with surgery (breast cancer in ÖUH and UUH; prostate cancer in NKUA) or radiotherapy (prostate cancer; ÖUH). One Hospital (Barcelona) will include breast cancer survivors (at least 12 months after surgery or chemotherapy) with follow-up through the Hospital. Finally, CareAcross will include patients with breast- or prostate cancer through its online platform for patients seeking for the CareAcross services. Inclusion Criteria (breast cancer; ORB and Uppsala): * breast cancer diagnosis * no clinical evidence of metastatic disease * able for curative treatment with surgery with or without oncological treatment. Inclusion Criteria (breast cancer; Barcelona) * prior early breast cancer who are at follow-up with at least 12 months after surgery or chemotherapy (whichever occurred last). Inclusion Criteria (breast cancer; CareAcross) * breast cancer diagnosis (as per self-reported) irrespective of stage and treatment. Inclusion Criteria (prostate cancer; SGHA and ORB) * proostate cancer diagnosis * no clinical evidence of metastatic disease * able for curative treatment with surgery with or without oncological treatment (SGHA) or radiotherapy (with or without prior surgery) irrespectively the type of radiotherapy (external radiotherapy, brachytherapy, or combination). Inclusion Criteria (prostate cancer; CareAcross) * prostate cancer diagnosis (as per self-reported) irrespective of stage and treatment. Exclusion Criteria (common in all study sites): * inability to give informed consent * inability / no access to smartphones, applications or internet services * patients with known medical history of allergy to the wearable material.
References
Publications (1)
- DERIVEDTzelves L, Manolitsis I, Varkarakis I, Ivanovic M, Kokkonidis M, Useros CS, Kosmidis T, Munoz M, Grau I, Athanatos M, Vizitiu A, Lampropoulos K, Koutsouri T, Stefanatou D, Perrakis K, Stratigaki C, Autexier S, Kosmidis P, Valachis A. Artificial intelligence supporting cancer patients across Europe-The ASCAPE project. PLoS One. 2022 Apr 21;17(4):e0265127. doi: 10.1371/journal.pone.0265127. eCollection 2022. PMID 35446854